CompletedPhase 2

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c 6.5-11%

Primary endpoint

•Effect of pramlintide on the PK of an oral medication

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00044707

Org study ID137-154

Timeline

Milestones

Study first posted2002-09-05estimated

Last update posted2015-05-21estimated

Study start2002-08 (month precision)

Primary completion2002-09actual (month precision)

Study completion2002-09actual (month precision)

Assets

Investigational agents

Pramlintide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age60 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

•Type 2 diabetes mellitus treated with diet and/or oral agents

•HbA1c 6.5-11.0

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

To determine the effect of pramlintide on the PK of an oral medication

Time frame:7 Days

concentration, descriptive

Secondary/protocol endpoint

safety and tolerability as measured by analysis of laboratory values and adverse events

Time frame:7 Days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.